RE:RE:RE:RE:RE:What's our Oncology Option Worth?Verification you're idea is on to something. Perhaps shows if you establish the validity of your
linker and homing receptor, you can spend loads of time and money experimenting around
with your platform in subsequent years. That's the massive value-add of these whole ADC/PDC
approach and why the valuations and take-out valuations are astounding.
Question, are you saying that TH1902 will have a higher payload of the treatment on an apples-to-apples
basis delivered into the tumor cell than Trodelvy? One thing seems clear from pre-clinical, TH-1902 crushes
Trodelvy on their Phase 3 neutropenia effect. I know, it's not humans, but it's looking good in little critters!
jfm1330 wrote: Took a look at Trodelvy.
They use a huge linker, a proprietary linker that is linked to the mAB through disulfide bond on cysteine.
The ratio of drug molecules vs mAB is 7.6. Which on a molecular weight basis is much lower than Thera's PDC.
Interserstingly, they are now testing the mAB of Trodelvy with Lu177...